drugset / Trial / NCT03551210
Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study was to evaluate the clinical efficacy of treatment with Nemonoxacin compared with Tavanic® in patients with community-acquired pneumonia (CAP).
Timeline
- Start
- 2016-05-04
- Primary completion
- 2017-12-13
- Completion
- 2017-12-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Levofloxacin | Small molecule | 500 mg | Intravenous |
| Subject | Nemonoxacin | Small molecule | 500 mg | Intravenous |